Ectin Research AB operates as a pharmaceutical company. The firm develops a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370, is under preclinical studies and aiming to treat metastatic bladder cancer, and other cancers such as breast, colorectal and prostate cancer cells. The company was founded by Christer Edlund, Marie-Lois Ivarsson, and Peter Falk on November 7, 2013 and is headquartered in Molndal, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company